Zura Bio Ltd

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

ZURA$1.41+13.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)


· · For the Three Months Ended
· · March 31
· 2025 · 2024
Operating expenses: · · · · ·
Research and development	$10,474	$3,593
General and administrative	8,780	4,786
Total operating expenses	19,254	8,379
Loss from operations	(19,254)	(8,379)
Other (income)/expense, net
Interest income	(1,817)	(1,215)
Change in fair value of private placement warrants	—	606
Other expense (income), net	5	(23)
Total other income, net	(1,812)	(632)
Loss before income taxes	(17,442)	(7,747)
Income tax benefit	—	—
Net loss	(17,442)	(7,747)
Adjustment of redeemable noncontrolling interest from redemption value to carrying value	—	7,017
Net loss attributable to Class A Ordinary Shareholders of Zura	$(17,442)	$(730)
Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted	$(0.19)	$(0.02)
Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted	92,964,048	46,914,542

Zura Bio Limited

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.